Regorafenib

證據等級: L5

預測適應症: 8 個

Regorafenib: From Colorectal Cancer / GIST to Liposarcoma

One-Sentence Summary

Regorafenib (Stivarga®) is an oral multikinase inhibitor approved in multiple major markets (FDA, EMA) for metastatic colorectal cancer, refractory gastrointestinal stromal tumour (GIST), and hepatocellular carcinoma, though it is not currently registered in Italy. The TxGNN model predicts it may be effective for Liposarcoma, a subtype of soft tissue sarcoma, with a prediction score of 99.76%. This direction is supported by 2 completed Phase 2 clinical trials specifically including liposarcoma cohorts and 9 publications, placing the overall evidence at Level L2.

Quick Overview

Item	Content
Original Indication	Not registered in Italy; globally approved for metastatic colorectal cancer, refractory GIST, and hepatocellular carcinoma
Predicted New Indication	Liposarcoma
TxGNN Prediction Score	99.76%
Evidence Level	L2
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Regorafenib is an oral multikinase inhibitor that broadly targets angiogenic kinases (VEGFR1–3, TIE2), stromal kinases (PDGFR-β, FGFR), and oncogenic kinases (KIT, RET, RAF). Its established efficacy in colorectal cancer, GIST, and HCC all rely on blocking tumour vascular dependence — a mechanism shared across many solid tumour types. Detailed mechanistic data was not available from the regulatory database for this report; however, the target profile is extensively described in published literature (e.g., PMID 30069758, 24756792).

Liposarcoma belongs to the soft tissue sarcoma (STS) family and its tumour microenvironment is heavily driven by VEGFR/PDGFR-mediated angiogenesis, particularly in the dedifferentiated subtype where MDM2/CDK4 amplification co-exists with active angiogenic signalling. Regorafenib's simultaneous blockade of VEGFR1–3 and PDGFR-β provides a biologically plausible mechanism for anti-tumour activity, especially in dedifferentiated liposarcoma with high angiogenic burden.

The most critical context, however, is that two randomized Phase 2 trials — REGOSARC (NCT01900743) and SARC024 (NCT02048371) — directly tested regorafenib in liposarcoma-specific cohorts. Both confirmed limited activity in the broad liposarcoma population: the REGOSARC trial demonstrated significant PFS improvement in non-adipocytic STS subtypes (leiomyosarcoma, synovial sarcoma) but not in the liposarcoma cohort; SARC024 similarly did not support routine use in liposarcoma overall. These findings suggest that while a biologically rational subpopulation may exist, patient selection criteria or combination strategies will be essential to realising clinical benefit.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01900743	Phase 2	Completed	219	REGOSARC: International, randomised, double-blind, placebo-controlled trial of regorafenib vs placebo in metastatic/unresectable STS after anthracycline failure. Includes a dedicated Liposarcoma cohort (Cohort A). Significant PFS improvement confirmed in non-adipocytic subtypes; liposarcoma cohort showed a trend but did not reach statistical significance (primary results: PMID 27751846).
NCT02048371	Phase 2	Completed	131	SARC024: Umbrella Phase 2 study of oral regorafenib across multiple sarcoma subtypes, each analysed independently. The liposarcoma cohort results (PMID 32701199) did not support routine use of regorafenib in this population; the authors conclude that novel therapies or combination approaches are warranted given limited treatment options.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27751846	2016	Randomized Phase 2 RCT	The Lancet Oncology	REGOSARC primary results: Regorafenib significantly improved PFS over placebo in non-adipocytic STS (leiomyosarcoma, synovial sarcoma, other subtypes); liposarcoma cohort did not meet the primary endpoint. Establishes differential activity by histological subtype.
32701199	2020	Randomized Phase 2 RCT	The Oncologist	SARC024 liposarcoma cohort: Confirms REGOSARC findings — regorafenib does not support routine use in the broad liposarcoma population. Emphasises need for novel therapies and combination approaches.
29902612	2018	Phase 2 Cross-over Analysis	European Journal of Cancer	Updated REGOSARC analysis including post-cross-over regorafenib activity: confirmed efficacy in non-adipocytic STS; liposarcoma (adipocytic) remains a subgroup without significant benefit. Provides long-term follow-up data.
33290314	2021	Retrospective Study	Anti-Cancer Drugs	Anlotinib in unresectable/metastatic well-differentiated/dedifferentiated liposarcoma. References that TKIs including regorafenib are approved in non-adipocytic STS, contextualising the class of agents in this disease and the unmet need in the adipocytic subtypes.
40975452	2025	Systematic Review	Critical Reviews in Oncology/Hematology	Systematic review of maintenance therapy strategies in advanced STS. Reviews eight randomized trials including regorafenib-based approaches, contextualising its role within the overall STS treatment landscape post-first-line doxorubicin.
28295221	2017	Phase 2 Secondary Analysis	Cancer	Q-TWiST analysis of REGOSARC: Integrated measure of clinical benefit (progression-free time + quality of life − toxicity time) in non-adipocytic sarcoma. Supports net clinical benefit of regorafenib when QoL and toxicity are factored in alongside PFS.
29931504	2018	Narrative Review	Targeted Oncology	Comprehensive review of regorafenib's growing role across STS subtypes (liposarcoma, leiomyosarcoma, GIST). Summarises Phase 2/3 trial data and discusses the varying activity by histological subtype.
25884155	2015	Trial Protocol	BMC Cancer	REGOSARC protocol paper: describes scientific rationale (angiogenesis as a key target in sarcoma biology), study design, stratification by histological subtype, and primary/secondary endpoints. Useful for understanding the trial's a priori hypotheses.
26266019	2015	Case Series (Indirect)	Rare Tumors	Pazopanib activity in metastatic Ewing sarcoma; provided the clinical rationale for expanding the SARC024 umbrella to include Ewing sarcoma alongside liposarcoma and osteosarcoma. Indirect reference supporting TKI class rationale in sarcoma.

Italy Market Information

Regorafenib is not currently registered in Italy (AIFA). No marketing authorizations were identified in the regulatory search conducted on 2026-03-29.

Note: Regorafenib (Stivarga®) holds marketing authorizations in other major regulatory jurisdictions, including the US (FDA, approved 2012 for mCRC; 2013 for GIST; 2017 for HCC) and the EU (EMA). Any compassionate use or named-patient access in Italy would need to follow AIFA's relevant provisions (e.g., Law 648/1996 or Article 3 of Law 79/2014).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — Multikinase Inhibitor (VEGFR/PDGFR/RAF/KIT/RET/FGFR inhibitor); not a conventional cytotoxic agent
Myelosuppression Risk	Low to moderate — thrombocytopenia and neutropenia are reported adverse events, but myelosuppression is generally less severe than with conventional cytotoxic chemotherapy
Emetogenicity Classification	Low — oral targeted therapy; nausea occurs but high-grade emesis is uncommon
Monitoring Items	Complete blood count (with differential and platelets), liver function tests (ALT, AST, bilirubin, alkaline phosphatase), serum creatinine, blood pressure, thyroid function, urinalysis for protein
Handling Protection	Follow institutional protocols for oral cytotoxic/targeted agent handling; standard precautions for preparation and disposal apply

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed, randomised Phase 2 trials (REGOSARC and SARC024) have directly investigated regorafenib in liposarcoma-specific cohorts, establishing an L2 evidence base. However, both trials showed that regorafenib does not provide significant benefit in the broad liposarcoma population — the effect is concentrated in non-adipocytic STS subtypes. Biological plausibility is genuine (VEGFR/PDGFR pathway dependence in dedifferentiated liposarcoma), but clinical development should target molecularly enriched subgroups rather than unselected patients.

To proceed, the following is needed:

Mechanistic data (MOA): Obtain from DrugBank API or Italy package insert to confirm kinase target profile relevant to liposarcoma biology
Safety documentation: Retrieve Italy/EMA package insert for complete warnings, contraindications, and drug interaction data; AIFA access pathway assessment
Patient selection criteria: Identify biomarker-defined subgroups in dedifferentiated liposarcoma (e.g., high angiogenic gene signature, VEGFR/PDGFR expression) most likely to respond to multikinase inhibition
Combination strategy exploration: Evaluate regorafenib + immunotherapy (PD-1/L1) or CDK4/6 inhibition combinations in dedifferentiated liposarcoma, where single-agent VEGFR targeting showed insufficient activity
Regulatory pathway: Define a compassionate use or named-patient access strategy under AIFA provisions given absence of Italian registration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.